Loading
Every dated change on the records linked to Primary myelofibrosis, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Intermediate/high-risk myelofibrosis with anaemia
Momelotinib improved symptom response, transfusion independence and spleen response compared with danazol; approved in September 2023.
A milestone in how this cancer is treated.
Myelofibrosis
Spleen volume reduction of 35 percent or more at 24 weeks in 41.
Spleen volume reduction of at least 35 percent at week 48 in 28 percent of patients on ruxolitinib against 0 percent on best available therapy; European approval in 2012.